For instance, Burnett et al. demonstrated that sustained trastuzumab treatment in HER2-positive breast cancer with PTEN (phosphatase and tensin-like protein) inactivation leads to resistance, induces a mesenchymal phenotype, and increases metastatic potential [28]. Here, ERBB2 is linked to breast carcinoma.